Entera Bio (ENTX) Total Debt (2017 - 2026)
Entera Bio (ENTX) posted quarterly Total Debt of $567000.0 for Q1 2026, up 10.1% year-on-year from $515000.0 in Q1 2025, and up 44.27% on a QoQ basis from $393000.0 in Q4 2025.
Entera Bio (ENTX) Total Debt (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has reported Total Debt for 3 consecutive years, with $567000.0 the latest figure, recorded in Q1 2026.
- Quarterly Total Debt rose 10.1% year-over-year to $567000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $567000.0 (up 10.1% YoY) and the FY2025 annual result came in at $393000.0, changed N/A from the prior year.
- Total Debt grew to $567000.0 in Q1 2026 per ENTX's latest filing, from $393000.0 in the prior quarter.
- Over the last five years, Total Debt for ENTX reached as high as $567000.0 in Q1 2026 and fell as low as $393000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 959.06 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | 567,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 567,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 524,000.00 |
| Mar 31, 2025 | 515,000.00 |
| Dec 31, 2017 | 3.89 Mn |